Long-Term Outcome After Allogeneic Hematopoietic Cell Transplantation For Myelofibrosis

This systemic review of 2,459 patients with myelofibrosis who underwent hematopoietic stem cell transplant (HSCT) showed that the “long-term survivor” cohort—1,055 patients who were alive and disease-free 2 years post-HSCT—demonstrated a 74% 10-year post-HSCT survival rate. Among all patients, the most common causes of death included disease recurrence, graft-versus-host disease, and infection, the latter of which was most common between 2- and 5-years after HSCT.